Check out that article in the show notes so you can be a little bit informed on BPC-157, and well get ahead of the influencers a little bit, but the more we know, the more we can have conversations, I think, with the people that are in front of us that trust us each and every day, so appreciate it
Goal intensity Aggressive goals justify more intensive protocols
The Bottom Line There is a reason the peptide space feels confusing: marketing has moved faster than regulation
What were building Neurophorol to enable (research-stage endpoints): receptor/pathway profiling + SAR learning neuroimmune and inflammation readouts oxidative stress / resilience markers reproducible preclinical validation workflows Were opening collaboration discussions with teams who can help validate and translate this platform responsibly: (Universities, Biotech companies, Tribal communities, and Investors) CB1/CB2 functional assays + signaling bias analytical chemistry (LCMS/NMR) + stability profiling neuroimmune models (microglia), biomarkers, preclinical design ADME/PK and translational study frameworks If you work in this space, comment NEUROPHOROL or DM your capability stack